MDR-TB and XDR-TB in Asia

MDR-TB and XDR-TB: drug resistance and treatment outcomes.

The subject is quite topical, as TB programmes and clinicians are searching for solutions to treat MDR/XDR-TB most effectively. Recently published studies and a systematic review have shown that XDR-TB is associated with higher probability of failure and death, and lower probability of treatment success than MDR-TB [2–7]. The XDR-TB-defining drugs have been studied to evaluate their role in det...

MDR / XDR - TB : where do we stand ?

Tuberculosis (TB) is one of the leading causes of death due to an infectious disease, second only to HIV/AIDS worldwide. It is estimated that approximately one third of the world’s population is infected with Mycobacterium tuberculosis, and 10% of infected individuals will develop active TB at some point in their lives. MDR-TB or multidrugresistant tuberculosis is a specific form of drug resist...

Statistics & Information of MDR and XDR TB in SAARC Region

TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged?

In spite of the growing awareness of emerging drug-resistant Mycobacterium tuberculosis, the extent of inappropriate tuberculosis (TB) case management may be underestimated, even in Europe. We evaluated TB case management in the European Union/European Economic Area countries, with special focus on multidrug-resistant (MDR) and extensively drug-resistant (XDR)-TB, using a purposely developed, s...

Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use.

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) remain significant global health challenges, with an annual incidence of approximately 480000 and 46000 cases, respectively [1]. Treatment outcomes in MDR-TB patients remain poor overall (52% success) and outcomes in XDR-TB patients are even more dismal (28% success) [1–3]. To improve these outcomes, new drugs are ...